Ivarmacitinib alone for rheumatoid arthritis after csDMARD failure
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a once-daily pill called Ivarmacitinib (a JAK inhibitor) taken alone to see if it can improve symptoms in people with rheumatoid arthritis who have not responded well to standard treatments like methotrexate. The study aims to find a more effective option for those who need better control of their RA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rheumatoid arthritis (RA) and have moderate to severe active disease (at least 6 tender or swollen joints, or a high disease activity score with elevated inflammation markers).
- You have tried at least one conventional DMARD (like methotrexate, sulfasalazine, hydroxychloroquine, or leflunomide) for at least 3 months, but it didn't work well enough or you couldn't tolerate it.
- You are not currently taking a combination of three conventional DMARDs (like methotrexate, hydroxychloroquine, and sulfasalazine together).
- You have not previously taken a JAK inhibitor (like tofacitinib or baricitinib) and had it fail to help your RA.
- You do not have serious health issues like uncontrolled infections, active tuberculosis, moderate to severe heart failure, recent heart attack or stroke, cancer (except some skin cancers), significant kidney disease, or are pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests different targeted treatments for people with rheumatoid arthritis who have tried one or two biologic or targeted synthetic drugs but still have symptoms. You need to be taking a stable dose of methotrexate.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.